TW202304516A - 用於降解α-突觸核蛋白聚集體之化合物及其用途 - Google Patents

用於降解α-突觸核蛋白聚集體之化合物及其用途 Download PDF

Info

Publication number
TW202304516A
TW202304516A TW111118050A TW111118050A TW202304516A TW 202304516 A TW202304516 A TW 202304516A TW 111118050 A TW111118050 A TW 111118050A TW 111118050 A TW111118050 A TW 111118050A TW 202304516 A TW202304516 A TW 202304516A
Authority
TW
Taiwan
Prior art keywords
compound
formula
alkyl
ethoxy
mmol
Prior art date
Application number
TW111118050A
Other languages
English (en)
Chinese (zh)
Inventor
張明奎
保羅 坦培思特
林易嫻
Original Assignee
香港商新旭生技股份有限公司
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 香港商新旭生技股份有限公司 filed Critical 香港商新旭生技股份有限公司
Publication of TW202304516A publication Critical patent/TW202304516A/zh

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/545—Heterocyclic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/55—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound the modifying agent being also a pharmacologically or therapeutically active agent, i.e. the entire conjugate being a codrug

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Treating Waste Gases (AREA)
TW111118050A 2021-05-14 2022-05-13 用於降解α-突觸核蛋白聚集體之化合物及其用途 TW202304516A (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
PCT/IB2021/054167 WO2022238737A1 (en) 2021-05-14 2021-05-14 Compounds for degrading alpha-synuclein aggregates and uses thereof
WOPCT/IB2021/054167 2021-05-14

Publications (1)

Publication Number Publication Date
TW202304516A true TW202304516A (zh) 2023-02-01

Family

ID=76034924

Family Applications (1)

Application Number Title Priority Date Filing Date
TW111118050A TW202304516A (zh) 2021-05-14 2022-05-13 用於降解α-突觸核蛋白聚集體之化合物及其用途

Country Status (8)

Country Link
EP (1) EP4337259A1 (https=)
JP (1) JP2024517340A (https=)
KR (1) KR20240008335A (https=)
CN (1) CN117377496A (https=)
AU (1) AU2021444937A1 (https=)
CA (1) CA3218573A1 (https=)
TW (1) TW202304516A (https=)
WO (1) WO2022238737A1 (https=)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN118845735A (zh) * 2024-06-21 2024-10-29 合肥综合性国家科学中心大健康研究院 金刚烷衍生物在制备离子通道tmem175激动剂中的应用

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2025162452A1 (zh) * 2024-01-29 2025-08-07 思努赛生物科技(上海)有限责任公司 一种识别α-突触核蛋白聚集体的化合物及其用途

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10300155B2 (en) * 2015-12-31 2019-05-28 Washington University Alpha-synuclein ligands
MX2019005007A (es) 2016-11-01 2019-07-18 Arvinas Inc Protac dirigidos a la proteína tau y métodos asociados de uso.
ES2965049T3 (es) 2017-07-12 2024-04-10 Dana Farber Cancer Inst Inc Compuestos para la degradación de la proteína tau
TW201946624A (zh) 2018-05-09 2019-12-16 新旭生技股份有限公司 雜芳基化合物及其用途
JP7297053B2 (ja) * 2018-08-20 2023-06-23 アルビナス・オペレーションズ・インコーポレイテッド 神経変性疾患を治療するためのｅ３ユビキチンリガーゼ結合活性を有するキメラ（ｐｒｏｔａｃ）化合物を標的とし、アルファ－シヌクレインタンパク質を標的とするタンパク質分解
PH12022500002A1 (en) * 2019-06-28 2023-04-03 Kymera Therapeutics Inc Irak degraders and uses thereof

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN118845735A (zh) * 2024-06-21 2024-10-29 合肥综合性国家科学中心大健康研究院 金刚烷衍生物在制备离子通道tmem175激动剂中的应用

Also Published As

Publication number Publication date
JP2024517340A (ja) 2024-04-19
CA3218573A1 (en) 2022-11-17
KR20240008335A (ko) 2024-01-18
WO2022238737A1 (en) 2022-11-17
AU2021444937A1 (en) 2023-11-30
CN117377496A (zh) 2024-01-09
EP4337259A1 (en) 2024-03-20

Similar Documents

Publication Publication Date Title
US12377152B2 (en) Compounds for degrading alpha-synuclein aggregates and uses thereof
JP7082446B2 (ja) スルホキシイミングリコシダーゼ阻害剤
AU2017222964B2 (en) Glycosidase inhibitors
CN115697990A (zh) 基于吲唑的化合物和相关使用方法
CA3044259A1 (en) Ire1 small molecule inhibitors
JP2011510044A (ja) シクロブトキシ基を含む化合物
TW202304516A (zh) 用於降解α-突觸核蛋白聚集體之化合物及其用途
JP2010506829A (ja) 新規な抗不安薬化合物
JP2023522078A (ja) １，５－ジヒドロ－２，４－ベンゾジアゼピン－３－オン誘導体及びその使用
AU7086900A (en) Heterocyclic ketone and thioester compounds and uses
TW201113290A (en) Novel fused thiazolo and oxazolo pyrimidinones
US20240132511A1 (en) Treatments of prader-willi syndrome
HK40080583A (en) 1,5-dihydro-2,4-benzodiazepine-3-one derivative and application thereof
HK40069557B (zh) 用於降解tau蛋白聚集体的化合物及其用途
KR20260028084A (ko) 모르폴린 및 1,4-옥사제판 화합물 및 요법에서의 이의 용도
AU2023355674A1 (en) Lactate enhancing compounds and uses thereof
HK40069557A (en) Compounds for degrading tau protein aggregates and uses thereof